paxlovid

Nirmatrelvir–ritonavir targeting viral persistence in post-COVID-19 condition long COVID in the USA RECOVER-VITAL: a randomised, double-blind, placebo-controlled, phase 2 trial Lindsey R Baden + 253 others BACKGROUND Post-acute sequelae of SARS-CoV-2 infection, more commonly known as long...

Nirmatrelvir for acute COVID-19 to prevent long COVID (PANORAMIC Norway): a double-blind, randomised, placebo-controlled trial, 2026, Oppegaard et al. Summary Background Long-term symptoms are common after acute COVID-19, particularly fatigue, cognitive problems, and dyspnoea. Cohort studies...

Paxlovid shows organ-specific and age-specific impacts on risk of developing post-acute sequelae of COVID-19 BACKGROUND The impact of antiviral therapies, including Paxlovid, on post-acute sequelae of COVID-19 (PASC) remains inconclusive. METHODS We analyzed data from 19,413 patients (age >...

Developing a platform protocol for clinical trials evaluating interventions that target proposed mechanisms of Long COVID: RECOVER-VITAL Background Long COVID, the chronic sequela of SARS-CoV-2 infection, has affected millions of people worldwide. However, its pathogenesis and treatment remain...

Exploratory analyses of Immunologic Features in a Randomized, Placebo-Controlled Trial of Nirmatrelvir/Ritonavir for Long COVID This exploratory analysis of PAX LC, a Phase 2, 1:1 randomized, double-blind, superiority, placebo-controlled trial examined whether treatment with...

Combination antiviral and anti-inflammatory therapy mitigates persistent neurological deficits in mice post SARS-CoV-2 infection Post-acute sequelae of COVID-19 (PASC) encompasses persistent neurological disease, including olfactory and cognitive dysfunction. The basis for this dysfunction is...

Nirmatrelvir/ritonavir use reduces risk for long COVID in patients with immunodeficiency [Line breaks added] Selected paragraphs Our findings highlight the potential broad benefit of nirmatrelvir/ritonavir in reducing the risk of long COVID among patients with both primary and secondary...

Association of COVID vaccinations and treatments with long COVID beyond 6 months: a case-control study on the adult population in a large integrated healthcare system in the United States from 2020 to 2023 Curtis Liu, Celina Liu, Rui Yan, Davida Becker, Jia Xiao Shi, Jeffrey Slezak, Diane Jerng...

Seems like the literature is confusing here. Consensus seems to be that no antivirals (AV) are effective against EBV. https://pmc.ncbi.nlm.nih.gov/articles/PMC6429425/ But then there are case studies showing certain AVs are effective. https://academic.oup.com/jid/article/216/2/198/3858428...

A thread to collect information and trial results to do with antivirals and LC, and discuss the covid-19 viral persistence hypothesis. Split from: Antivirals as an ME/CFS treatment (e.g. valacyclovir, valgancyclovir, amantadine) Null result for paxlovid in a decent sized blinded long covid...

Nirmatrelvir–ritonavir versus placebo–ritonavir in individuals with long COVID in the USA PAX LC: a double-blind, randomised, placebo-controlled, phase 2, decentralised trial Mitsuaki Sawano; Bornali Bhattacharjee; César Caraballo; Rohan Khera; Shu-Xia Li; Jeph Herrin; Dany Christian; Andreas...

Risk of Post-Acute Sequelae of COVID-19 and Oral Antivirals in Adults Aged Over 60 years: A Nationwide Retrospective Cohort Study Hyejin Jooa, Eunji Kimc, Kyungmin Huhd, Gi Hwan Baea, Hyungmin Leee, Jungyeon Kime, Dong-Hwi Kime, Min-Gyu Yooe, Il Uk Joi, Poong Hoon Leei, Geun Woo Leei, Hee Sun...

Hospitalizations and Mortality Among Older Adults With and Without Restricted Access to Nirmatrelvir-Ritonavir John N. Mafi, Sitaram Vangala, Moira K. Kapral, Peter E. Wu, Manying Cui, Artem Romanov, Katherine L. Kahn Abstract Randomized clinical trials of nirmatrelvir-ritonavir found reduced...

Anticoagulant vs. antiviral therapy, recovery and neurodamage in Long COVID: a real-world prospective cohort study Marc Jamoulle, Margaux Mignolet, Isabelle Meyts, Aurelie Ladang, Charles Nicaise, Johan Van Weyenbergh [Line breaks added] Abstract Recent estimates consider that Long COVID...

Real-World Effectiveness of Nirmatrelvir in Protecting Long COVID for Outpatient Adult Patients – A Large-Scale Observational Cohort Study from the RECOVER Initiative Fei Wang; Chengxi Zang; Haoyang Li; Dhru Khullar; Yongkang Zhang; Stephenson Strobel; Yong Chen; Marc Sala; Payal Patel...

Effect of Paxlovid Treatment on Long COVID Onset: An EHR-Based Target Trial Emulation from N3C Alexander Preiss; Abhishek Bhatia; Chengxi Zang; Leyna V Aragon; John M Baratta; Monika Baskaran; Frank Blancero; M Daniel Brannock; Robert F Chew; Ivan Diaz; Megan Fitzgerald; Elizabeth P Kelly...

The study reveals a higher-than-previously-reported number of patients experienced a rebound after Paxlovid treatment, challenging previous assumptions. Despite receiving Paxlovid, individuals with long COVID exhibited similar symptoms to those who didn’t receive the treatment. However, the...

Nirmatrelvir/ritonavir and risk of long COVID symptoms: A retrospective cohort study We conducted a retrospective cohort study to assess whether treatment with nirmatrelvir/ritonavir was associated with a reduced risk of long COVID. We enrolled 500 adults with confirmed SARS-CoV-2 who were...

Medpage Today Stanford Study of Paxlovid for Long COVID Stopped Early Quote: Two sources familiar with the STOP-PASC study told MedPage Today that trial enrollment had been halted. One was told by a study coordinator that a preliminary review found "inconclusive evidence" for the primary...

imPROving Quality of LIFe In the Long COVID Patient (PROLIFIC) https://clinicaltrials.gov/ct2/show/NCT05823896 Petter Brodin Karolinska Institutet, Sweden "Brief Summary: The purpose of this study is to investigate the efficacy of orally administered nirmatrelvir/ritonavir compared with...